((自动化翻译由路透提供，请见免责声明 ))
10月21日 - ** 远程保健公司Mangoceuticals （又称MangoRx）的股票在收盘前下跌4%，至2.43美元
** 礼来公司 起诉包括MangoRx在内的三家 (link) 医疗水疗中心和在线销售商，指控它们销售声称含有其流行减肥药Zepbound的主要成分--替扎帕肽的产品。
** 本月早些时候，MangoRx 推出了自己的品牌 "Trim"--一种复方口服可溶解的替西帕肽片剂。
** 礼来公司称，MangoRx 在销售一种口服版本，尽管没有任何研究表明这种配方安全有效。
** MangoRx 还销售 "Slim"，它是semaglutide 的口服复方制剂，semaglutide 是诺和诺德 Wegovy 的活性成分。
** MangoRx 没有立即回应置评请求
** 截至上一交易日收盘，MGRX年累计下跌近42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.